Post Operative Pain Relief News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET News provided by Share this article Share this article CUPERTINO, Calif., May 4, 2021 /PRNewswire/  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update. Q1 2021 Accomplishments: Initiated patient dosing in the Phase 2b AHFIRM clinical study of DUR-928 in severe Alcohol-associated Hepatitis (AH) FDA approval of POSIMIR in adults to produce post-surgical analgesia for up to 72 hours following Arthroscopic Subacromial Decompression Publication of DUR-928 s mechanism of action Appointment of two highly experienced biopharmaceutical board members

United statesJamese brownHuman servicesDrug administrationCompany epigenetic regulator programExchange commissionEpigenetic regulator programJournal of lipid researchUs department of healthCorporation nasdaqAgency for healthcare researchClinical developmentAlcohol associated hepatitisArthroscopic subacromial decompressionSelected programsTrack designation